Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use.

ABSTRACT:

Background

Vasodilatory shock refractory to catecholamine vasopressors and arginine vasopressin is highly morbid and responsible for significant mortality. Synthetic angiotensin II is a potent vasoconstrictor that may be suitable for use in these patients.

Research question

What is the safety and effectiveness of angiotensin II and what variables are associated with a favorable hemodynamic response?

Study design and methods

We performed a multicenter, retrospective study at five tertiary medical centers in the United States. The primary end point of hemodynamic responsiveness to angiotensin II was defined as attainment of mean arterial pressure (MAP) of ≥ 65 mm Hg with a stable or reduced total vasopressor dosage 3 h after drug initiation.

Results

Of 270 includ

SUBMITTER: Wieruszewski PM 

PROVIDER: S-EPMC7856533 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature